{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreifmkognzefhubfjtcrbl5vvm2r2inrcpf2suys4brehbmavswad4i",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mhj62x4wibe2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiakxbjruwwr6c3olb6r3q43p3lxch7urgbzqhybsn2o7hbzkitmoi"
    },
    "mimeType": "image/jpeg",
    "size": 145661
  },
  "path": "/news/2026-03-weight-loss-drug-semaglutide-alzheimer.html",
  "publishedAt": "2026-03-20T14:20:04.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "Oral semaglutide (a GLP-1 pill) is not effective at slowing progression in patients with mild Alzheimer's disease, finds the first large Phase III randomized controlled trials on the topic published in The Lancet.",
  "title": "Weight-loss drug semaglutide does not slow Alzheimer's disease, two clinical trials find"
}